| Literature DB >> 32586060 |
Sylwester Ślusarczyk1, F Sezer Senol Deniz2, Renata Abel1,3, Łukasz Pecio4, Horacio Pérez-Sánchez5, José P Cerón-Carrasco6, Helena den-Haan5, Priyanka Banerjee3, Robert Preissner3, Edward Krzyżak7, Wiesław Oleszek4, Ilkay E Orhan2, Adam Matkowski1.
Abstract
Inhibition of cholinesterases remains one of a few available treatment strategies for neurodegenerative dementias such as Alzheimer's disease and related conditions. The current study was inspired by previous data on anticholinesterase properties of diterpenoids from Perovskia atriplicifolia and other Lamiaceae species. The acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) inhibition by the three new natural compounds-(1R,15R)-1-acetoxycryptotanshinone (1), (1R)-1-acetoxytanshinone IIA (2), and (15R)-1-oxoaegyptinone A (3)-as well as, new for this genus, isograndifoliol (4) were assessed. Three of these compounds exhibited profound inhibition of butyrylcholinesterase (BChE) and much weaker inhibition of acetylcholinesterase (AChE). All compounds (1-4) selectively inhibited BChE (IC50 = 2.4, 7.9, 50.8, and 0.9 µM, respectively), whereas only compounds 3 and 4 moderately inhibited AChE (IC50 329.8 µM and 342.9 µM). Molecular docking and in silico toxicology prediction studies were also performed on the active compounds. Natural oxygenated norditerpenoids from the traditional Central Asian medicinal plant P. atriplicifolia are selective BChE inhibitors. Their high potential makes them useful candidate molecules for further investigation as lead compounds in the development of a natural drug against dementia caused by neurodegenerative diseases.Entities:
Keywords: cholinesterases; molecular docking; structure elucidation; tanshinones
Mesh:
Substances:
Year: 2020 PMID: 32586060 PMCID: PMC7352922 DOI: 10.3390/ijms21124475
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Figure 1Structures of compounds 1–4 isolated from roots of Perovskia atriplicifolia.
H (500 MHz) and C (125 MHz) NMR data of 1–3 in methanol-d4 (δ in ppm, J in Hz) *.
| Position | 1 | 2 | 3 | |||
|---|---|---|---|---|---|---|
| δC type | δH ( | δC type | δH ( | δC type | δH ( | |
| 1 | 68.7, CH | 6.40, t (3.4) | 69.0, CH | 6.41, t (3.4) | 201.8, C | |
| 2 | 25.5, CH2 | 2.13–2.19, m | 25.6, CH2 | 2.13–2.19, m | 37.3, CH2 | 2.90, t (7.2) |
| 3 | 33.1, CH2 | 1.93, td (13.3, 2.6) | 33.2, CH2 | 1.93, td (13.1, 2.4) | 37.5, CH2 | 2.10, t (7.2) |
| 4 | 35.9, C | 35.8, C | 36.4, C | |||
| 5 | 154.2, C | 151.9, C | 138.7, C | |||
| 6 | 134.9, CH | 7.84, d (7.7) | 135.7, CH | 7.89, d (8.3) | 157.9, C | |
| 7 | 126.4, CH | 7.67, d (7.8) | 124.2, CH | 7.80, d (8.3) | 131.7, CH | 7.78 |
| 8 | 128.3, C | 129.6, C | 128.6, C | |||
| 9 | 130.1, C | 128.2, C | 134.2, C | |||
| 10 | 138.1, C | 138.7, C | 128.2, CH | 7.78 | ||
| 11 | 184.5, C | 183.8, C | 184.9, C | |||
| 12 | 176.3, C | 176.3, C | 178.9, C | |||
| 13 | 119.6, C | 121.1, C | 120.4, C | |||
| 14 | 172.7, C | 162.7, C | 172.0, C | |||
| 15 | 35.7, CH | 3.48–3.58, m | 122.3, C | 35.8, CH | 3.54–3.64, m | |
| 16 | 83.2, CH2 | 143.6, CH | 7.48, q (1.3) | 83.6, CH2 | ||
| 17 | 18.7, CH3 | 1.32, d (6.8) | 8.8, CH3 | 2.23, d (1.2) | 18.8, CH3 | 1.347, d (6.9) |
| 18 | 31.3, CH3 | 1.28, s | 31.2, CH3 | 1.31 s | 28.9, CH3 | 1.352, s |
| 19 | 31.9, CH3 | 1.39, s | 31.9, CH3 | 1.41, s | 28.9, CH3 | 1.350, s |
| 1- | 171.8 | 172.2 | ||||
| 1- | 21.0 | 1.99, s | 21.0 | 2.01, s | ||
* Overlapped signals are reported without designating multiplicity.
Figure 2HMBC correlations of compounds 1–3.
Cholinesterase (AChE and BChE) inhibition by the four isolated compounds (1–4) and their content (mg g−1 D.W.) in roots of Perovskia atriplicifolia measured using Diode-Array Detector (DAD)-HPLC.
| Compound Number | Compound | % Inhibition ± S.D. at 10.0 µg·mL−1 | BChE Inhibition IC50 | Ki app * | Content in Dried Roots | ||
|---|---|---|---|---|---|---|---|
| AChE | BChE | µg·mL−1 | µM | µM | mg (100 g)−1 | ||
|
|
| 22.8 ± 2.4 | 95.9 ± 0.0 | 0.84 ± 0.09 | 2.37 | 1.34 | 28.5 ± 2.5 |
|
|
| 28.0 ± 0.9 | 85.3 ± 4.3 | 2.77 ± 0.48 | 7.86 | 4.59 | 8.1 ± 0.4 |
|
|
| 49.6 ± 1.8 | 87.3 ± 1.0 | 15.75 ± 1.12 | 50.80 | 30.0 | 21.3 ± 0.7 |
|
|
| 50.0 ± 1.8 | 98.6 ± 0.0 | 0.27 ± 0.02 | 0.89 | 0.47 | 302.0 ± 9.1 |
|
|
| 97.2 ± 2.9 | 86.8 ± 2.9 | 28.16 ± 1.51 | 76.4 | --- | -------------- |
* for assumed competitive inhibition, substrate concentration = 1 mM. ** reference drug.
Figure 32D depiction of main interactions established between compounds 1–4 and BChE. The green continuous line represents hydrophobic interactions while the black dashed lines correspond to hydrogen bonds. (A) 2D depiction of main interactions established between compound 1 and BChE. (B) 2D depiction of main interactions established between compound 2 and BChE. (C) 2D depiction of main interactions established between compound 3 and BChE. (D) 2D depiction of main interactions established between compound 4 and BChE.
Figure 4Interactions of isolated compounds (purple skeleton) that interact with both AChE and BChE, in transparent grey cartoon fashion. The left column (A,C) corresponds to AChE while the right column (B,D) corresponds to BChE. The first and second rows correspond to (15R)-1-oxoaegyptinone A (A,B) and isograndifoliol (C,D), respectively. Residues are colored according to their binding areas as yellow (catalytic triad) and green (peripheral anionic site). Hydrogen bonds established between compounds and depicted residues are shown with deep yellow dashed lines.
Figure 5Interactions of isolated compounds from Perovskia atriplicifolia extracts (purple skeleton) that only interact with BChE, in transparent grey cartoon fashion. Shown compounds are (1R,15R)-1-acetoxycryptotanshinone (A), and (1R)-1-acetoxytanshinone IIA (B). Residues are colored according to their binding areas as yellow (catalytic triad) and green (peripheral anionic site). Hydrogen bonds established between compounds and depicted residues are shown with deep yellow dashed lines.
Results obtained from computational toxicity prediction using the ProTox-II platform.
| Compound Name | Predicted LD50 Value and Tox class | Prediction Accuracy (%) | Toxicity Targets | Avg Similarity to Known Ligands (%) | Toxicity Endpoints | Prediction Probability | Cytochrome Inhibition Prediction |
|---|---|---|---|---|---|---|---|
| 260 (mg/kg), | 54.26 | - | - | Immunotoxicity |
| - | |
| 1230 (mg/kg), | 54.26 | - | - | Immunotoxicity |
| CYP2C9 (62%) | |
| 260 (mg/kg), | 54.26 | - | - | Immunotoxicity |
| - | |
| 2000 (mg/kg) | 68.27 | Glucocorticoid Receptor | 73.25 | - | - | CYP3A4 (78%) | |
| Progesterone Receptor | 72.37 | CYP2C9 (63%) |
Results obtained from computational prediction using the admetSAR platform.
| Compounds | Blood-Brain Barrier | Probability | Water Solubility (logS) | Lipophilicity (AlogP) | Plasma Protein Binding (100 %) | Human Intestinal Absorption | Probability |
|---|---|---|---|---|---|---|---|
| positive | 0.97 | −4.43 | 3.51 | 0.89 | positive | 0.99 | |
| positive | 0.93 | −4.42 | 4.31 | 1.06 | positive | 0.98 | |
| positive | 0.96 | −3.78 | 3.08 | 0.95 | positive | 0.99 | |
| positive | 0.93 | −4.28 | 3.06 | 0.82 | positive | 0.99 |